The Paradoxical Induction of Crohn's Disease Following Treatment of Psoriatic Arthritis with Etanercept
Forouzandeh, M.; Vazquez, T.; Nouri, K.; Forouzandeh, B.
Journal of Drugs in Dermatology Jdd 18(8): 832-834
2019
ISSN/ISBN: 1545-9616 PMID: 31424717 Document Number: 17935
INTRODUCTION: While psoriasis, psoriatic arthritis, and Crohn's Disease (CD) all share a common central pathogenesis pathway and a wide overlap of treatment regime, discrepancies still exist and are highlighted by the variability in the effectiveness of certain immunomodulating agents. Etanercept, for example, has been shown to be ineffective in CD due to its inability to induce T-cell apoptosis in the intestinal mucosa.
Document emailed within 1 workday
Related Documents
De Vlam, K.; Bruhwyler, J.; Boone, C. 2016: Maintenance of remission and monotherapy status over 66 months in patients with psoriatic arthritis receiving etanercept Clinical and Experimental Rheumatology 34(6): 1094-1097Lindqvist, U.; Wernroth, M.-L.; Husmark, T.; Larsson, P.; Geijer, M.; Teleman, A.; Theander, E.; Alenius, G.-M. 2017: DAPSA, DAS28 and MDA predict long-term treatment regime in psoriatic arthritis. the Swedish Early Psoriatic Arthritis Cohort Clinical and Experimental Rheumatology 35(6): 936-942
Kimball, A.B.; Jackson, J.M.; Sobell, J.M.; Boh, E.E.; Grekin, S.; Pharmd, E.B.Y.; Woolley, J.M.; Xia, H.A.; Chiou, C.-F.; Stevens, S.R. 2007: Reductions in healthcare resource utilization in psoriatic arthritis patients receiving etanercept therapy: results from the educate trial Journal of Drugs in Dermatology: Jdd 6(3): 299-306
Di Nuzzo, S.; Zanni, M.; De Panfilis, G. 2007: Exacerbation of paranoid schizophrenia in a psoriatic patient after treatment with cyclosporine A, but not with etanercept Journal of Drugs in Dermatology: Jdd 6(10): 1046-1047
Cohen, M.R.; Reda, D.J.; Clegg, D.O. 1999: Baseline relationships between psoriasis and psoriatic arthritis: analysis of 221 patients with active psoriatic arthritis. Department of Veterans Affairs Cooperative Study Group on Seronegative Spondyloarthropathies Journal of Rheumatology 26(8): 1752-1756
Jaller Char, J.J.; Jaller, J.A.; Waibel, J.S.; Bhanusali, D.G.; Bhanusali, N. 2018: The Role of IL-17 in the Human Immune System and its Blockage as a Treatment of Rheumatoid Arthritis, Ankylosing Spondylitis, and Psoriatic Arthritis Journal of Drugs in Dermatology: Jdd 17(5): 539-542
D'Amore, M.; Minenna, G.; Nigro, A.; Favia, I.; D'Amore, S. 2005: Etanercept in the treatment of rheumatoid arthritis. A case report Recenti Progressi in Medicina 96(4): 187-189
Pratsidou-Gertsi, P.; Trachana, M.; Pardalos, G.; Kanakoudi-Tsakalidou, F. 2010: A follow-up study of patients with juvenile idiopathic arthritis who discontinued etanercept due to disease remission Clinical and Experimental Rheumatology 28(6): 919-922
Auer, I.O.; Röder, A.; Mittelstaedt, A. 1985: Treatment of Crohn's disease using Colibiogen. Cellular reactions of the immune system in patients with Crohn's disease Fortschritte der Medizin 103(46): 1076-1080
Bathon, J.M.; Fleischmann, R.M.; Van der Heijde, Désirée.; Tesser, J.R.; Peloso, P.M.; Chon, Y.; White, B. 2006: Safety and efficacy of etanercept treatment in elderly subjects with rheumatoid arthritis Journal of Rheumatology 33(2): 234-243
Tiliakos, A.N.; Tiliakos, N.A. 2003: Ocular inflammatory disease in patients with RA taking etanercept: is discontinuation of etanercept necessary? Journal of Rheumatology 30(12): 2727
Theiss, B. 1971: Are there typical skin manifestations in psoriatic arthritis and psoriatic spondylarthritis? Der Hautarzt; Zeitschrift für Dermatologie Venerologie und verwandte Gebiete 22(2): 63-68
Salvarani, C.; Lo Scocco, G.; Macchioni, P.; Cremonesi, T.; Rossi, F.; Mantovani, W.; Battistel, B.; Bisighini, G.; Portioli, I. 1995: Prevalence of psoriatic arthritis in Italian psoriatic patients Journal of Rheumatology 22(8): 1499-1503
Patrizi, A.; Venturi, M.; Scorzoni, R.; Pazzaglia, M.; Malavolta, N.; Bardazzi, F. 2014: Nail dystrophies, scalp and intergluteal/perianal psoriatic lesions: risk factors for psoriatic arthritis in mild skin psoriasis? Giornale Italiano di Dermatologia e Venereologia: Organo Ufficiale Societa Italiana di Dermatologia e Sifilografia 149(2): 177-184
Alenius, G-Marie.; Friberg, C.; Nilsson, S.; Wahlström, J.; Dahlqvist, S.Rantapää.; Samuelsson, L. 2004: Analysis of 6 genetic loci for disease susceptibility in psoriatic arthritis Journal of Rheumatology 31(11): 2230-2235
Kousa, M.; Tilikainen, A.; Karvonen, J.; Lassus, A. 1976: Psoriatic arthritis and Reiter's disease. HLA antigens in mixed cases Annals of Clinical Research 8(5): 312-316
Vojvodich, P.Fernandez.; Hansen, J.B.; Andersson, U.; Sävendahl, L.; Hagelberg, S. 2007: Etanercept treatment improves longitudinal growth in prepubertal children with juvenile idiopathic arthritis Journal of Rheumatology 34(12): 2481-2485
Sukenik, S.; Giryes, H.; Halevy, S.; Neumann, L.; Flusser, D.; Buskila, D. 1994: Treatment of psoriatic arthritis at the Dead Sea Journal of Rheumatology 21(7): 1305-1309
Martin, B.C.; Thomas, L.W.; Dann, F.J. 2017: Apremilast for the treatment of psoriatic arthritis Dermatology Online Journal 23(2)
Papagoras, C.; Voulgari, P.V.; Drosos, A.A. 2013: Atherosclerosis and cardiovascular disease in the spondyloarthritides, particularly ankylosing spondylitis and psoriatic arthritis Clinical and Experimental Rheumatology 31(4): 612-620